Oncolytics Biotech Inc T.ONC

90 days

[westcoast1000]

Inthno nailed it by saying pancan would not be likely to take a risk on the CI selected for the trial. They would likely go with what worked with pela in the Goblet results presented at the beginning of June. 

When ONCY's involvement was announced, they stated that details of the trial would be available in 90 days. In other words the CI will be selected by then.

IN three months,  the updated panc, as well as the first set of results from CRC and the two anal cancer trials will be available to Roche and ONCY, assuming those results will be presented at the ESMO conference on Oct 23, 2023.

In other words, all the information will be there on the panc side and other results from the Goblet trial, to allow informed bids. 

Look for something to happen on the partnership/buyout front by around then.

I am hoping for an equity investment by a big pharma that will raise our share price to a substantial level, and then allow for a full buyout subsequent to that. Alternatively a bidding war between Roche, Merck and Pfizer would also get the price we hope for.  I will leave it to others to offer views on the value.

[Noteable]

Equally,  ONCY could be acquired by a Big Pharma in 90 days.

[jimsenior]

@westcoast1000. I refer you to the news release March 21, 2022. There were two mCRC cohorts and one anal. Cohort 4 anal did not require a safety run-in nor did Cohort 2 first-line MSImCRC, but Cohort 3, third-line mCRC did. It is an interestimg release, and may be the key to the endgame. I think last weeks news gave us numerous avenues; credit to those involved. Cheers

[askretka]

Scooter on ST did a pretty deep dive into colorectal cancer and came up with some pretty interesting stuff.    Matt said in one of his recent interviews that " It probably works in colorectal."    They put pancreatic cancer, colorectal and anal together as  a group hoping to get something positive out of it. The Pancreatic results were a surprise. Dr Vile said

[itntdf]

if a partnership/buyout were to occur around the esmo conference in october, 2023, it doesn't appear that would be based on anything associated with the pancan arrangement. as stated in oncy's press release: Oncolytics expects to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint inhibitor

[westcoast1000]

Thanks inthno, I was referring to the choice of the CI for the trial, not the outcome of the trial.

[Noteable]

ONCY' acquirer could also be the one to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024, even moreso given the new developments that ONCY initiated with PanCan.

[Noteable]

ONCY's de Guttadauro stated that he was working towards having one Big Pharma company take both the mBC and the pancreatic Phase 3 clinical studies through to approval, particularly now that pelareorep is set-up for Accelerated Approval in both indications. Also Roche has guided that the company was focusing on having Tecentriq to advance the company in the immuno-oncology global market space

[Noteable]

Roche's Tecentriq and paclitaxel previously failed to improve outcomes for patients with PD-L1-positive metastatic TNBC in the IMpassion131 trial. That phase 3 setback, plus pressure from the FDA, led Roche to voluntarily withdraw its accelerated approval for Tecentriq in combination with Bristol Myers Squibb’s Abraxane, or nab-paclitaxel, in 2021. Since 2021, ONCY has been able to

[Noteable]

Roche said it had “been working diligently” with the FDA to find another post-approval pathway for its Tecentriq combo. Roche's intent on moving the accelerated approval process forward, seems to favorabley position ONCY's for a strong Phase 3 pelareorep in combination with paclitaxel study in mBC, alongside another Phase 3 study now planned with PanCan in pancreatic cancer. 

[Noteable]

June 01, 2023 - atezolizumab cancer research focus. https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-marginal-zone-b-cell-lymphoma-likelihood-of-approval/

[Noteable]

une 01, 2023 - atezolizumab cancer research focus. This is the list of Roche's development activity with atezolizumab with the highlighted cancers having relevance to tecentriq in combination with ONCY's pelareorep. Atezolizumab (RG7446) is under development for the treatment of poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC), recurrent glioblastoma

[Noteable]

Disregard  - HER positive and PD-L1 positive breast cancer

[westcoast1000]

That is very helpful Noteable. If pela works well with even a few of them, it is a blockbuster aquisition for Roche. Tecentriq already accounts for a major share of Roche pharma revenues. Combining with pela would effectively extend their patents also.

[askretka]

Roche is the most likely candidate,  but Merck did a  Pancreatic study first and had ok results but it was considered a failure, 42% ? achieved stable disease I think but I don't think they filled the trial either?  Matt said he got a call as trial kept going and some of Patients were " Still alive" That was mentioned in one of quarterly reports quite awhile ago

[fox7mf]

Let's get set for another prosperous week SP wise. I imagine more investors, who were late in digesting last weeks incredible news, will move in. I also imagine ONCY, at the hands of Coffey, Rigby and Parsons, will be a fine oiled machine from here on out, with regularly scheduled drops to keep the SP moving to the point where we need to be before b/o. This week could see the publication of